U.S. stock markets have been enduring severe volatility over the past month. Wall Street’s recent turmoil is broad-based. The ...

The company’s success has been largely built on its HIV treatment portfolio, including the blockbuster drug Biktarvy. Gilead has demonstrated strong operational execution, effectively ...

In the first study, presented by Dr Amy Colson of Community Research Initiative, Boston, people with HIV taking one of the most commonly prescribed regimens, Biktarvy (bictegravir / emtricitabine / ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Previous research has suggested an increased risk for neuropsychiatric symptoms in people living with HIV who are being treated with INST (Integrase Strand Transfer) inhibitor antiretrovirals, Gillian ...

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 ...